BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 11718156)

  • 21. [Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials].
    Mitry E; Ducreux M; Rougier P
    Bull Cancer; 1998 Dec; Spec No():38-42. PubMed ID: 9932083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. European experience with irinotecan plus fluorouracil/folinic acid or mitomycin.
    Khayat D; Gil-Delgado M; Antoine EC; Coeffic D; Benhammouda A; Grapin JP; Bastian G
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):64-7. PubMed ID: 9726094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Irinotecan: toward clinical end points in drug development.
    Pazdur R
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):13-21. PubMed ID: 9726086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure.
    Schmitt C; Blijham G; Jolain B; Rougier P; Van Cutsem E
    Anticancer Drugs; 1999 Jul; 10(6):617-23. PubMed ID: 10885910
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Setting a new standard--irinotecan (Campto) in the second-line therapy of colorectal cancer: final results of two phase III studies and implications for clinical practice.
    Cunningham D
    Semin Oncol; 1999 Feb; 26(1 Suppl 5):1-5. PubMed ID: 10213008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. UFT plus calcium folinate/irinotecan in colorectal cancer.
    Twelves C
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):51-4. PubMed ID: 10442362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methods for evaluating effects of an irinotecan + 5-fluorouracil/leucovorin (IFL) regimen in an orthotopic metastatic colorectal cancer model utilizing in vivo bioluminescence imaging.
    Surguladze D; Steiner P; Prewett M; Tonra JR
    Methods Mol Biol; 2010; 602():235-52. PubMed ID: 20012402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Irinotecan may extend survival in people with metastatic colorectal cancer.
    Oncology (Williston Park); 1998 Oct; 12(10):1512. PubMed ID: 9798204
    [No Abstract]   [Full Text] [Related]  

  • 29. US pivotal studies of irinotecan in colorectal carcinoma.
    Pitot HC
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):48-53. PubMed ID: 9726091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Irinotecan in colorectal cancer].
    Pozzo C; Cassano A; Barone C
    Tumori; 2001; 87(1 Suppl 1):S49-50. PubMed ID: 11300023
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparing irinotecan with best supportive care and infusional 5-fluorouracil: a critical evaluation of the results of two randomized phase III trials.
    Wilke HJ
    Semin Oncol; 1999 Feb; 26(1 Suppl 5):21-3. PubMed ID: 10213011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group.
    Cunningham D; Glimelius B
    Semin Oncol; 1999 Feb; 26(1 Suppl 5):6-12. PubMed ID: 10213009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials].
    Van Cutsem E; Peeters M
    Bull Cancer; 1998 Dec; Spec No():33-7. PubMed ID: 9932082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of irinotecan in colorectal cancer.
    Saltz LB
    Curr Oncol Rep; 1999; 1(2):155-60. PubMed ID: 11122813
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A risk-benefit assessment of irinotecan in solid tumours.
    Siu LL; Rowinsky EK
    Drug Saf; 1998 Jun; 18(6):395-417. PubMed ID: 9638386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Irinotecan in the first-line treatment of colorectal cancer.
    Saltz LB
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):54-8. PubMed ID: 9726092
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update on European adjuvant trials with irinotecan for colorectal cancer.
    Douillard JY; Barbarot V; Bennouna J
    Oncology (Williston Park); 2002 Apr; 16(4 Suppl 3):13-5. PubMed ID: 12014862
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Colorectal cancer: Irinotecan therapy-following a trail of breadcrumbs?
    Goldberg RM; O'Neil BH
    Nat Rev Gastroenterol Hepatol; 2009 Sep; 6(9):507-9. PubMed ID: 19713983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Irinotecan (CPT-11) in patients with advanced colorectal cancer previously treated with 5-fluorouracil-based chemotherapy.
    Aravantinos G; Skarlos DV; Kosmidis P; Georgoulias V; Sgouros I; Bafaloukos D; Androulakis N; Florou S; Fountzilas G
    Crit Rev Oncol Hematol; 1999 Dec; 32(3):209-19. PubMed ID: 10633850
    [No Abstract]   [Full Text] [Related]  

  • 40. [A case of sigmoid colon cancer with temporary dysarthria associated with irinotecan].
    Sogabe S; Yuki S; Takano H; Kobayashi Y; Nakatsumi H; Sasaki T; Kawamoto Y; Fukushima H; Iwanaga I; Uehata Y; Komatsu Y; Asaka M
    Gan To Kagaku Ryoho; 2011 Aug; 38(8):1375-7. PubMed ID: 21829085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.